Impact of Socioeconomic Status on Long COVID & Quality of Life | French Nationwide Study 🇫🇷 #LongCOVID #Pencis

INTRODUCTION

The long-term consequences of SARS-CoV-2 infection, known as long COVID or post-COVID-19 condition (PCC), have emerged as a significant public health concern worldwide. In France, the burden of long COVID on individuals' quality of life remains a pressing issue, particularly as it interacts with socioeconomic disparities. This study investigates the role of socioeconomic position (SEP) in modulating the relationship between PCC and health-related quality of life (HRQoL) using data from a representative sample following the Omicron wave in autumn 2022. Through the application of the PROMIS-29 questionnaire across eight HRQoL domains, the research aims to uncover how variables like education, employment, income, and geographic origin shape the lived experience of long COVID in the French population. The study not only quantifies the impact but also explores equity and vulnerability across social strata, highlighting the importance of integrating socioeconomic perspectives into public health responses and healthcare strategies for long COVID.

RESEARCH DESIGN AND METHODOLOGY

The study utilized a cross-sectional, population-representative design to examine long COVID’s impact on HRQoL post-Omicron. A total of 1,448 adults previously infected with SARS-CoV-2 were surveyed, integrating robust demographic and socioeconomic data. The research adopted the WHO definition of PCC and employed the PROMIS-29 instrument to measure HRQoL across domains like physical function, pain, sleep, and mental well-being. A conceptual model was proposed to test how modifying factors—including age, sex, and SEP indicators such as education, employment status, and income—alter the relationship between PCC and HRQoL. Advanced statistical modeling techniques allowed for the analysis of interaction effects and helped identify subgroups with the most severe impacts.

SOCIOECONOMIC DETERMINANTS OF HRQOL

SEP was found to be a critical determinant in the relationship between long COVID and HRQoL. Individuals with low educational attainment and lower household income reported significantly greater reductions in quality of life across five PROMIS-29 domains, particularly in depression, fatigue, and social participation. These findings underscore the systemic vulnerability of marginalized groups to post-infection consequences. The study also revealed that business owners, unemployed individuals, and those from mainland France suffered disproportionately, suggesting economic instability and regional disparities amplify PCC-related health burdens. SEP is therefore not just a background factor but a core component influencing HRQoL outcomes post-COVID.

IMPACT OF EMPLOYMENT STATUS AND OCCUPATIONAL CATEGORY

Among the SEP indicators, employment status and occupational category were key modifiers. Unemployed individuals and self-employed persons, including entrepreneurs, exhibited greater HRQoL impairment than other employment groups. This pattern may be attributed to financial insecurity, lack of health coverage, and reduced social support. Moreover, these findings raise important considerations for labor policies and workplace support systems in mitigating the impact of long COVID, especially in populations whose income and well-being are tightly coupled to continuous employment or business viability.

REGIONAL AND EDUCATIONAL DISPARITIES

Geographic origin and educational attainment significantly modified the PCC-HRQoL relationship. Participants from mainland France experienced more pronounced declines in HRQoL, pointing to regional disparities that may stem from differences in healthcare access, economic infrastructure, or social services. Similarly, individuals without a long tertiary education were more vulnerable to PCC-related impairments. These disparities indicate that educational and regional policy interventions must be integrated into public health responses to long COVID to ensure equitable recovery and resilience across diverse French communities.

POLICY IMPLICATIONS AND RECOMMENDATIONS

The study’s findings carry significant implications for healthcare providers and policymakers. The evidence clearly supports the need for targeted interventions that consider SEP when addressing long COVID. Public health strategies must go beyond clinical treatment and incorporate social support, income assistance, and educational outreach to mitigate long COVID’s unequal burden. Special attention should be given to unemployed individuals, low-income families, and those with limited education. Policymakers are urged to design equity-focused programs to strengthen HRQoL recovery for all, especially for the socially and economically vulnerable populations.

🔗 Visit: https://infectious-diseases-conferences.pencis.com
🏅 Nominate Now: https://infectious-diseases-conferences.pencis.com/award-nomination/?ecategory=Awards&rcategory=Awardee
📝 Register: https://infectious-diseases-conferences.pencis.com/award-registration/
📩 Contact: infectioussupport@pencis.com

HASHTAGS:

#LongCOVID, #PostCOVID19Condition, #HealthInequality, #SocioeconomicStatus, #HRQoL, #PublicHealthFrance, #PROMIS29, #COVIDRecovery, #HealthEquity, #HealthPolicy, #OmicronWave, #FrenchHealthStudy, #SocialDeterminants, #HealthResearch, #ChronicCOVID, #IncomeAndHealth, #EmploymentHealthLink, #MentalHealthCOVID, #EducationAndHealth, #PCCImpact,

Declining Myocarditis Mortality in the U.S. 📉 | COVID-19 Pandemic Impact Explained #Myocarditis #Pencis

INTRODUCTION

Myocarditis, an inflammatory condition of the heart muscle, is associated with severe clinical complications including cardiogenic shock and life-threatening arrhythmias. In the United States, the trends of myocarditis-related mortality over the last two decades have been largely understudied, particularly in the context of the COVID-19 pandemic. This study aimed to analyze the temporal patterns, demographic disparities, and pandemic-era deviations in myocarditis mortality using national death records from 1999 to 2023, sourced from the CDC WONDER database. Through robust statistical methodologies including Joinpoint Regression and excess death calculations in R Studio, the study reveals a nuanced shift in mortality risk over time. A decline in deaths over two decades was disrupted dramatically during COVID-19, highlighting the need to understand infectious triggers and healthcare inequities. With nearly three-fourths of excess deaths in 2021 involving COVID-19, this investigation underscores the pandemic’s profound cardiovascular consequences and its intersection with existing health disparities across sex, race, and age.

LONG-TERM MORTALITY TRENDS FROM 1999 TO 2019

From 1999 to 2019, the age-adjusted mortality rate (AAMR) for myocarditis declined significantly in the United States. Beginning at 7.40 deaths per 1 million population in 1999, the rate dropped by 46.08% to 3.99 per million in 2019. This sustained decrease suggests improved healthcare access, earlier detection, or advancements in clinical management of myocarditis over time. The annual percentage change (APC) of −2.59 (95% CI: −2.97 to −2.24) reflects this favorable trend. However, this apparent progress masks underlying demographic disparities that persisted throughout the period. Despite the improvement, specific subpopulations—particularly older adults and Black Americans—continued to experience higher rates of mortality. These findings call attention to the need for targeted public health strategies and resource allocation to ensure that such declines in mortality are equitable and sustainable across all communities.

PANDEMIC-ERA SURGE IN MORTALITY: 2020–2021

The COVID-19 pandemic had a dramatic impact on myocarditis mortality trends, reversing two decades of progress within just two years. Between 2019 and 2021, the AAMR surged from 3.99 to 5.85, a 46.62% increase. The APC for this period reached 22.3%, a statistically significant and alarming shift. The year 2021 saw the highest excess mortality, with myocarditis deaths 54.94% above the expected number based on pre-pandemic trends. This reversal not only highlights the role of SARS-CoV-2 in triggering or exacerbating myocarditis but also indicates how strained healthcare systems and delayed care during the pandemic may have compounded outcomes. The sudden increase suggests an urgent need for both real-time surveillance systems and longitudinal research to track cardiac complications during infectious disease outbreaks.

COVID-19 AS A CONTRIBUTOR TO EXCESS MORTALITY

COVID-19 infection emerged as a dominant co-factor in excess myocarditis mortality during the pandemic. From 2020 to 2023, approximately 70.33% of the excess myocarditis-related deaths also involved confirmed COVID-19 infection. In 2021, this figure peaked at 76.15%, suggesting a strong association between SARS-CoV-2 and increased myocarditis risk or exacerbation of preexisting cardiac inflammation. The underlying mechanisms may include direct viral injury to myocardial cells, hyperinflammatory responses, and vascular involvement. These findings reinforce the broader impact of COVID-19 beyond respiratory illness, emphasizing its role in multisystem complications including cardiovascular mortality. It also points toward the necessity for COVID-related myocarditis awareness, early detection protocols, and post-infection cardiac monitoring, especially in vulnerable populations.

DISPARITIES IN DEMOGRAPHIC AND REGIONAL MORTALITY

The data from 1999 to 2023 consistently showed that myocarditis-related mortality was not equally distributed across demographics. Males, non-Hispanic Black or African Americans, and older adults bore a disproportionately higher burden. These disparities may stem from a combination of socioeconomic factors, comorbid conditions, healthcare access, and potential biological susceptibilities. The pandemic further magnified these inequities, with certain communities experiencing more profound surges in myocarditis deaths. This emphasizes the need for equity-driven health policy, focused interventions, and improved access to cardiac care in historically underserved regions and populations. Additionally, regional differences must be analyzed in future studies to determine if localized healthcare infrastructure or viral exposure played a role.

MORTALITY RECOVERY POST-PANDEMIC PEAK

Although the peak in myocarditis-related mortality occurred in 2021, subsequent years have shown partial recovery. By 2023, the AAMR had decreased to 4.33 per million, a reduction from the pandemic peak but still above the pre-pandemic baseline. This incomplete return to previous levels suggests a lasting impact of COVID-19 on cardiac health or residual healthcare disruptions. While it is encouraging that mortality rates declined after 2021, the persistent elevation underscores the importance of long-term follow-up for patients affected during the pandemic years. Continued monitoring and preventive strategies, including vaccination, post-acute COVID care, and cardiovascular rehabilitation, are vital in addressing the residual burden of myocarditis in the U.S. population.

Visit: https://infectious-diseases-conferences.pencis.com
Nominate Now: https://infectious-diseases-conferences.pencis.com/award-nomination/?ecategory=Awards&rcategory=Awardee
Registration page: https://infectious-diseases-conferences.pencis.com/award-registration/
Contact us: infectioussupport@pencis.com

HASHTAGS

#Myocarditis, #CardiacHealth, #MortalityTrends, #COVID19Impact, #PandemicEffect, #PublicHealthResearch, #CardiovascularDisease, #HeartInflammation, #Epidemiology, #CDCWONDER, #JoinpointAnalysis, #ExcessDeaths, #HealthDisparities, #CardiacMortality, #HeartDiseaseStats, #COVID19Myocarditis, #RStudioAnalysis, #DemographicTrends, #HealthEquity, #USMortalityData,

Global Threat: Klebsiella Pneumoniae Carbapenemase (KPC) Resistance | #AMR #KPC #Pencis

🧬 INTRODUCTION

Klebsiella pneumoniae carbapenemases (KPCs) represent a significant class A β-lactamase threat among Gram-negative bacteria, known for their capacity to hydrolyze a wide spectrum of β-lactams, including carbapenems—the last line of defense in treating multidrug-resistant infections. This study aimed to systematically evaluate the global distribution, prevalence, and resistance patterns of KPC-producing Gram-negative bacterial clinical isolates. The comprehensive analysis incorporated data from 119 eligible studies out of 1993 screened articles, covering all major continents and offering a critical snapshot of KPC's global burden. These organisms, especially Klebsiella pneumoniae and Escherichia coli, are increasingly implicated in nosocomial outbreaks and community infections that pose severe challenges to current antibiotic therapies. This research reinforces the urgency to adopt robust infection control protocols and antimicrobial stewardship measures on a global scale.

🌍 GLOBAL DISTRIBUTION OF KPC-PRODUCING BACTERIA

The review confirms the widespread global distribution of KPC-producing Gram-negative pathogens. Asia led the published data with 49 studies, followed by Europe (29), North America (14), South America (11), and Africa (3), with an additional 13 studies spanning multiple continents. This wide geographic representation underscores the critical reality that no region remains unaffected. While high-income countries have reported relatively advanced detection and surveillance systems, resource-limited nations may underreport due to infrastructure constraints. The global reach of these resistant pathogens calls for international collaboration in monitoring and response mechanisms. Mobility of populations, international trade, and travel play key roles in the dissemination, making KPCs a true global public health concern.

🔬 MOLECULAR CHARACTERISTICS AND GENE DETECTION

The genetic characterization of the KPC-producing isolates revealed a dominant presence of the blaKPC-2 and blaKPC-3 genes. Among the studies evaluating specific genes, 91% (52/57) identified blaKPC-2, while 46% (26/57) reported blaKPC-3, indicating the prevalence of these two alleles in global outbreaks. These genes are frequently located on transferable plasmids, enhancing their potential for interspecies transmission. The molecular epidemiology of KPCs is essential not only for diagnostics but also for tracking the emergence of new resistant clones. Genetic surveillance helps in understanding local versus imported cases, guiding infection control policies. Continued research in this area is vital for early detection and tailored therapeutic strategies.

🦠 DIVERSITY OF BACTERIAL SPECIES PRODUCING KPC

While Klebsiella pneumoniae remains the most common KPC-producer (96 studies), the enzyme's presence in multiple other species indicates widespread gene dissemination. These include Escherichia coli (52), Enterobacter cloacae (31), Citrobacter spp. (24), and even less common isolates like Raoultella spp. and Morganella spp. This species diversity increases the difficulty of detection and treatment, especially in settings where laboratory capacity is limited. The evolution of resistance across a broad spectrum of clinically significant bacteria suggests that resistance is no longer restricted to a single genus but is rather an ecosystem-level threat. This highlights the need for comprehensive species-specific surveillance to understand the complete clinical burden.

💊 RESISTANCE PATTERNS AND TREATMENT CHALLENGES

One of the critical observations from the analysis is the resistance patterns displayed by these organisms. Resistance to ceftazidime–avibactam remained low (0–4%), making it one of the most promising therapeutic agents. However, resistance to other agents like polymyxins (4–80%), tigecycline (0–73%), and trimethoprim–sulfamethoxazole (5.6–100%) was more variable and often alarmingly high. These findings reflect the shrinking therapeutic arsenal available to clinicians. Multidrug resistance among KPC-producing isolates not only leads to limited treatment options but also results in increased morbidity, mortality, and healthcare costs. These resistance patterns call for the urgent development of novel antimicrobials and optimization of combination therapies.

🛡️ RECOMMENDATIONS AND GLOBAL IMPLICATIONS

The global rise in KPC-producing organisms necessitates immediate action through comprehensive infection control strategies, including enhanced hand hygiene, contact precautions, and environmental decontamination. Equally important are antimicrobial stewardship programs to curb the inappropriate use of broad-spectrum antibiotics. International guidelines should support the integration of rapid molecular diagnostic tools and real-time data-sharing platforms. Given the ability of KPC genes to rapidly disseminate across species and continents, a “One Health” approach that encompasses human, animal, and environmental health is required. Without a coordinated global response, KPCs could escalate into an untreatable pandemic-level antimicrobial resistance crisis.

Visit: https://infectious-diseases-conferences.pencis.com
Nominate Now: https://infectious-diseases-conferences.pencis.com/award-nomination/?ecategory=Awards&rcategory=Awardee
Registration page: https://infectious-diseases-conferences.pencis.com/award-registration/
Contact us: infectioussupport@pencis.com

HASHTAGS

#KPCResistance, #AntimicrobialResistance, #KlebsiellaPneumoniae, #BetaLactamase, #GlobalHealthThreat, #GramNegativeBacteria, #SuperbugCrisis, #DrugResistance, #CarbapenemResistance, #InfectionControl, #GlobalEpidemiology, #MultidrugResistance, #HospitalInfections, #MolecularDiagnostics, #AntibioticStewardship, #ResistanceSurveillance, #blaKPC2, #blaKPC3, #NovelAntibiotics, #MicrobialGenomics,

Antimicrobial Resistance in Diabetic UTI Patients | Tanzania Study 🔬 #AMR #UTI #Diabetes #Pencis

INTRODUCTION

Urinary tract infections (UTIs) are among the most common bacterial infections globally and are a significant source of morbidity, particularly among vulnerable populations such as diabetic patients. Individuals with diabetes mellitus (DM) are more prone to infections due to compromised immune responses, making them especially susceptible to genitourinary tract infections. This vulnerability, combined with the frequent use of antibiotics to manage UTIs, has contributed to the growing public health crisis of antimicrobial resistance (AMR). In Tanzania, particularly at Benjamin Mkapa Hospital in Dodoma, the burden of antimicrobial resistance is intensifying among diabetic patients diagnosed with UTIs. The indiscriminate use of antibiotics—often without prescriptions—has exacerbated the emergence of resistant uropathogens, leading to prolonged hospital stays, increased healthcare costs, and treatment failures. This research was conducted to assess the prevalence and associated factors of AMR in diabetic UTI patients and to identify actionable insights for clinical management and public health interventions.

METHODOLOGICAL INSIGHTS

This research adopted a hospital-based cross-sectional study design, enrolling 419 diabetic patients aged 30 years and above diagnosed with urinary tract infections at Benjamin Mkapa Hospital. The methodological rigor was maintained by collecting a single urine specimen from each patient and culturing it on both Cystine Lactose Electrolyte Deficient (CLED) and blood agar media. The purpose was to isolate and identify the causative organisms responsible for UTIs in this population. Data were statistically analyzed using SPSS version 20, with descriptive analysis expressed in proportions and percentages. The study further utilized logistic regression to determine associations between antimicrobial resistance and sociodemographic factors. This methodological approach ensured both the reliability and relevance of the findings in terms of identifying key behavioral and socioeconomic contributors to antibiotic resistance among diabetic UTI patients.

SOCIOECONOMIC DETERMINANTS OF AMR

The study found a strong statistical association between antimicrobial resistance and several socioeconomic factors, including employment status and income level. Working participants exhibited higher levels of antimicrobial resistance (P = 0.000), and similarly, jobless participants were also significantly associated with AMR (P = 0.000), indicating a complex socio-behavioral dynamic. Low-income individuals (P = 0.046) also showed increased prevalence of resistant infections. These findings underscore the need to consider socioeconomic determinants when designing interventions to combat AMR. Awareness campaigns and healthcare strategies must be tailored not only to medical needs but also to economic realities, which often influence access to healthcare, drug affordability, and adherence to prescription guidelines.

MISUSE OF ANTIBIOTICS AND PUBLIC BEHAVIOR

One of the most alarming revelations of this study was the high correlation between antibiotic misuse and the rise of antimicrobial resistance. A significant number of patients admitted to using antibiotics without prescriptions (P = 0.001), which directly contributed to the proliferation of resistant uropathogens. This highlights a critical gap in public health literacy regarding the proper use of antibiotics. Over-the-counter access, lack of regulation, and limited awareness have created an environment where antibiotics are used as quick fixes, often without any microbiological confirmation. Public education, stricter prescription enforcement, and community engagement programs are essential to curb irrational drug use and reduce AMR risks.

MICROBIOLOGICAL CULTURE OUTCOMES

The culturing of urine samples on CLED and blood agar media yielded crucial data on the types of pathogens involved and their resistance patterns. The microbiological analysis served as the backbone of this research, providing empirical evidence to support the prevalence of resistant strains among diabetic UTI patients. These findings are not only important for local treatment guidelines but also contribute to the larger body of global AMR surveillance. Periodic bacterial culture testing and sensitivity profiling should be institutionalized in hospital settings, especially for high-risk groups like diabetics, to ensure targeted antibiotic therapy and minimize empirical treatment that fuels resistance.

RECOMMENDATIONS AND PUBLIC HEALTH IMPLICATIONS

This study concludes with a call to action for healthcare policymakers, practitioners, and community leaders. The results clearly point toward the urgent need for regular epidemiological surveillance of antibiotic resistance patterns, particularly among diabetic patients with UTIs. Public education campaigns must be intensified to promote the responsible use of antibiotics. Hospital infection control protocols should include routine culture and sensitivity testing to guide appropriate treatment. Additionally, socioeconomic disparities must be addressed through policy interventions that improve healthcare access and patient education. Only a coordinated, multidisciplinary approach can effectively halt the growing threat of antimicrobial resistance in vulnerable populations.

Visit: https://infectious-diseases-conferences.pencis.com
Nominate Now: https://infectious-diseases-conferences.pencis.com/award-nomination/?ecategory=Awards&rcategory=Awardee
Registration page: https://infectious-diseases-conferences.pencis.com/award-registration/
Contact us: infectioussupport@pencis.com

Hashtags

#UTIResearch, #AntimicrobialResistance, #DiabeticHealth, #UTITanzania, #BenjaminMkapaHospital, #DodomaHealthStudy, #InfectiousDiseases, #PublicHealthCrisis, #BacterialResistance, #DiabetesAndInfection, #HospitalBasedStudy, #CrossSectionalResearch, #AMRinUTI, #AntibioticMisuse, #ResistanceSurveillance, #MicrobialResistance, #Uropathogens, #CLEDMedia, #HealthPolicy, #GlobalHealthChallenge

🏆 Best Paper Award 2025 | Recognizing Excellence in Research | #Pencis #BestPaperAward #InfectiousDiseases

🏆 INTRODUCTION

The Best Paper Award 2025, a premier recognition presented by Pencis Conferences, shines a spotlight on pioneering scientific work that has the power to transform the field of infectious diseases and public health. Celebrated as one of the most prestigious honors in the academic world, this award is more than a trophy—it's a testament to innovation, rigor, and real-world impact. With a meticulous peer-review process guided by top-tier scholars and research leaders, the award validates research excellence while nurturing a global scientific community. Winners are invited to present their groundbreaking findings at the International Conference on Infectious Diseases, fostering deeper conversations and international collaboration. The award serves as both a motivator and a milestone, inspiring researchers—whether emerging talents or seasoned professionals—to push the boundaries of what science can achieve. As global health threats continue to challenge our systems, recognizing and rewarding innovation in this space has never been more critical.

🔬 RESEARCH EXCELLENCE IN INFECTIOUS DISEASES

Scientific research in infectious diseases is a cornerstone of global health resilience, and the Best Paper Award 2025 places a sharp focus on elevating this critical domain. The award is a tribute to original work that not only deepens our understanding of pathogen biology and epidemiology but also brings new therapeutic and preventive strategies to light. Whether it's combatting viral outbreaks, drug-resistant bacteria, or neglected tropical diseases, the selected research represents cutting-edge science at its finest. The awardees are pioneers whose work has the potential to influence policy, drive medical innovation, and protect communities around the world. Their contributions reflect a commitment to excellence, backed by data-driven insights and novel methodologies that redefine public health outcomes.

🌍 GLOBAL IMPACT AND PUBLIC HEALTH SIGNIFICANCE

One of the defining attributes of the Best Paper Award is its emphasis on research that generates a measurable global impact. In a world where emerging infectious diseases threaten societal stability, the award highlights studies that not only advance scientific knowledge but also provide solutions with direct application to public health systems. From improving vaccine efficacy to developing rapid diagnostics and effective surveillance methods, winning papers serve as blueprints for tackling real-world challenges. The award inspires researchers to transcend academic boundaries and engage with the pressing health issues faced by underserved populations globally. Through these efforts, science becomes a driving force for health equity and international preparedness.

🧠 INNOVATION THROUGH INTERDISCIPLINARY RESEARCH

Innovation thrives at the crossroads of disciplines, and the Best Paper Award 2025 recognizes this by honoring research that integrates fields such as microbiology, data science, epidemiology, and immunology. Award-winning papers often embody a fusion of ideas, using technological advancements like AI, genomics, or bioinformatics to solve complex health problems. This interdisciplinary approach not only boosts research relevance but also accelerates the translation of findings into actionable health strategies. By rewarding boundary-breaking work, the award encourages a spirit of intellectual curiosity and collaboration across disciplines, nurturing a generation of researchers equipped to tackle evolving public health threats.

🤝 COLLABORATION AND NETWORKING OPPORTUNITIES

Winning the Best Paper Award is not only a personal achievement but also a gateway to global collaboration. Awardees are invited to present their work at the Pencis-hosted International Conference on Infectious Diseases, where they can engage with researchers, clinicians, policymakers, and funders from around the world. These interactions pave the way for cross-border projects, knowledge exchange, and long-term scientific partnerships. The award strengthens the global research network by connecting like-minded experts dedicated to a common goal—defending humanity against infectious disease threats. This collaborative ecosystem is critical for advancing research and accelerating innovations that benefit all.

🎓 ENCOURAGING EARLY-CAREER RESEARCHERS

The Best Paper Award 2025 is designed not only to honor established scholars but also to empower emerging voices in science. By providing early-career researchers with recognition, visibility, and a platform to showcase their work, the award helps shape the future of public health research. Young investigators are encouraged to submit high-quality, original studies, knowing that their efforts will be reviewed and appreciated by leaders in the field. This inclusive approach builds confidence, fosters mentorship, and supports the next wave of innovators who will carry forward the mission of combating infectious diseases worldwide.

Visit: https://infectious-diseases-conferences.pencis.com
Nominate Now: https://infectious-diseases-conferences.pencis.com/award-nomination/?ecategory=Awards&rcategory=Awardee
Registration page: https://infectious-diseases-conferences.pencis.com/award-registration/
Contact us: infectioussupport@pencis.com

Hashtags

#BestPaperAward2025, #PencisConferences, #InfectiousDiseases, #PublicHealthResearch, #GlobalHealth, #ScientificExcellence, #ResearchRecognition, #AcademicAwards, #HealthInnovation, #PeerReview, #ResearchLeadership, #MedicalScience, #GlobalCollaboration, #DiseasePrevention, #ScientificBreakthroughs, #AwardWinningResearch, #ConferencePresentation, #PublicHealthImpact, #ScientificAchievement, #PencisAwards

Deep Learning Unveils Liver Metastasis Risks in Pancreatic Cancer | Genomic AI Model 🔬 #PancreaticCancer #AIModel #LiverMetastasis #pencis

                                                       

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis and high rate of occult metastasis at initial diagnosis, significantly limiting the benefit of local surgical treatment. Despite advances in imaging and staging, many patients with resectable disease eventually show early systemic relapse, indicating a need for improved risk stratification methods. The integration of genomic insights with artificial intelligence models has the potential to reshape how we classify tumor biology preoperatively. This study introduces a novel deep learning framework, PanScore, which combines eight critical genomic features to predict liver metastasis, the most lethal dissemination site in PDAC. By stratifying patients based on survival risk, PanScore moves beyond conventional radiological and pathological staging. This research paves the way for applying precision oncology in pancreatic cancer, offering a new avenue for optimizing surgical decisions and systemic therapy planning.

GENOMIC FEATURE SELECTION FOR RISK STRATIFICATION

The foundation of PanScore’s predictive power lies in its careful selection of genomic biomarkers associated with metastatic potential in PDAC. Through retrospective analysis of the MSK-MET dataset, the study pinpointed eight key genomic alterations with strong statistical correlation to liver metastasis: tumor mutational burden (TMB), fraction genome altered (FGA), TP53 mutation status, and copy number variations in AKT2, MYC, KRAS, CDKN2A, and SMAD4. These features not only meet the prevalence threshold of 2.5% but also exhibit significant p-values (<0.05), underscoring their clinical relevance. This precise feature curation forms a crucial step in ensuring model interpretability and performance, demonstrating the importance of biologically informed input selection in deep learning for oncology.

MODEL DEVELOPMENT AND ARCHITECTURE OPTIMIZATION

The PanScore model was developed using the H2O AutoML platform, which facilitates rapid construction and evaluation of various machine learning models. Using five-fold cross-validation and AUC-based ranking, the most accurate model was fine-tuned into a six-layer deep neural network. Hyperparameter optimization ensured the model's robustness across training datasets. The use of automated machine learning workflows allowed systematic evaluation of different architectures and learning parameters, improving generalizability. By leveraging this approach, the study ensured that PanScore maintains high predictive accuracy while remaining adaptable to future datasets and potentially scalable for clinical applications.

SURVIVAL STRATIFICATION AND PROGNOSTIC VALIDATION

A key achievement of PanScore is its ability to stratify patients into three clinically distinct survival risk categories: low, intermediate, and high. Within the MSK-MET cohort, these risk groups demonstrated significantly different median overall survival times (21.39, 15.34, and 9.36 months, respectively; p < 0.001). The hazard ratio for high vs. low-risk groups was 2.07, indicating a strong prognostic signal. Independent validation using the MSK-IMPACT dataset (n=2181) further confirmed these distinctions. For patients with radiographically resectable PDAC, PanScore identified subgroups with survival ranging from 35.4 to 17.9 months—information not captured by conventional staging. This robust validation highlights PanScore’s potential as a reliable biomarker-driven tool in clinical oncology.

IMPLICATIONS FOR RESECTABLE PDAC AND OCCULT METASTASIS

One of PanScore’s most impactful findings is its capacity to uncover biologically aggressive PDAC phenotypes among radiographically resectable cases. In the MSK-IMPACT validation cohort, patients deemed resectable yet assigned a high PanScore exhibited survival outcomes similar to those with borderline or locally advanced disease. This suggests that PanScore may detect molecular signatures of occult metastasis not visible on imaging. Such insights can inform preoperative decision-making, potentially guiding neoadjuvant therapy or delaying surgery in favor of systemic treatment. This has profound implications for improving the precision of PDAC management and reducing early post-surgical relapse.

FUTURE DIRECTIONS AND CLINICAL INTEGRATION

The integration of PanScore into clinical workflows may herald a new era in PDAC care, where treatment planning is informed not only by anatomical staging but also by underlying tumor biology. Future research should focus on prospective validation across multi-institutional cohorts, testing its predictive value in real-time clinical settings. Additionally, integrating PanScore with imaging, histopathology, and other omics data could enhance its predictive capability. As deep learning tools become increasingly accepted in oncology, regulatory approval, interpretability, and clinician education will be key for adoption. Ultimately, PanScore holds promise for enabling a more personalized and evidence-based approach to managing pancreatic cancer.

Visit: https://infectious-diseases-conferences.pencis.com
Nominate Now: https://infectious-diseases-conferences.pencis.com/award-nomination/?ecategory=Awards&rcategory=Awardee
Registration page: https://infectious-diseases-conferences.pencis.com/award-registration/
Contact us: infectioussupport@pencis.com

HASHTAGS

#PanScore, #PDAC, #PancreaticCancer, #DeepLearning, #GenomicMedicine, #AIinOncology, #CancerGenomics, #LiverMetastasis, #PrecisionOncology, #MachineLearning, #SurvivalPrediction, #Bioinformatics, #MSKIMPACT, #MSKMET, #TumorBiomarkers, #TP53, #KRAS, #CDKN2A, #SMAD4, #H2OAutoML,

BRCA2 Pre-mRNA Splicing Breakthrough: Hope for Fanconi Anemia D1 Patients | #Pencis #BRCA2 #GeneTherapy

 

INTRODUCTION

Fanconi anemia (FA) is a genetically heterogeneous disorder with a critical deficiency in DNA repair pathways, leading to chromosomal instability, progressive bone marrow failure, congenital abnormalities, and elevated cancer risk. Among the various FA subtypes, FA-D1 is particularly severe and is linked to biallelic pathogenic variants (PVs) in the BRCA2 gene, also known as FANCD1. This gene plays an essential role in homologous recombination repair, and its complete loss is embryonically lethal. Yet, FA-D1 patients survive, indicating the presence of residual BRCA2 function despite damaging PVs. This paradox has spurred investigations into alternative molecular mechanisms, such as hypomorphic mutations or aberrant splicing, that could rescue partial BRCA2 activity. Of particular interest is the splicing behavior in the 5′ region of the BRCA2 transcript, which may enable the production of partially functional proteins, especially in the intrinsically disordered N-terminal domain. Understanding these compensatory mechanisms provides not only insight into FA-D1 pathology but also into broader cancer biology and therapeutic strategies involving BRCA2 function.

MECHANISMS OF RESIDUAL BRCA2 FUNCTION IN FA-D1

Despite pathogenic biallelic mutations in BRCA2, FA-D1 patients display partial protein functionality, prompting detailed exploration of the underlying mechanisms. One key mechanism involves hypomorphic missense mutations, which produce proteins with reduced but viable activity. Another involves translation re-initiation after premature stop codons, enabling expression of downstream BRCA2 segments. Aberrant splicing, especially in the 5′ segment, appears to generate alternative transcripts that preserve critical domains of BRCA2, ensuring survival. These findings raise critical questions about the flexibility of genetic regulation and how non-canonical translational and splicing events contribute to cellular resilience. These survival strategies offer crucial insights into both DNA repair mechanisms and potential therapeutic interventions in BRCA2-related cancers.

ALTERNATIVE SPLICING IN THE 5′ SEGMENT OF BRCA2

Splicing anomalies in the 5′ region of BRCA2 play a pivotal role in preserving residual function in FA-D1. This region, which encodes an intrinsically disordered segment, is particularly susceptible to alternative or aberrant splicing events that may skip exons harboring mutations. Such events may lead to the generation of partially functional isoforms that escape nonsense-mediated decay and retain enough structural integrity to support DNA repair. The high variability of 5′ splicing suggests an adaptive cellular mechanism to mitigate deleterious mutations. Ongoing research aims to catalogue these splice variants and assess their functional contribution to DNA repair in FA-D1 patients, highlighting the therapeutic potential of modulating RNA splicing.

BIOLOGICAL IMPLICATIONS OF INTRINSICALLY DISORDERED BRCA2 DOMAINS

The N-terminal region of BRCA2, rich in intrinsically disordered sequences, plays a non-structured but functionally significant role in protein-protein interactions and regulatory dynamics. Pathogenic variants in this region might be buffered by alternative splicing, especially in FA-D1 patients. Disordered regions are known for their structural plasticity, allowing compensatory structural remodeling even when exon skipping occurs. Understanding the biochemical flexibility of these domains offers a new dimension to interpreting the pathogenicity of mutations and their downstream effects on DNA repair. This concept also sheds light on broader questions regarding protein disorder and stability in genetic diseases beyond Fanconi anemia.

THERAPEUTIC POTENTIAL OF SPLICING MODULATION IN BRCA2-RELATED DISORDERS

The identification of functional BRCA2 splice variants in FA-D1 opens potential avenues for therapeutic intervention through splicing modulation. Antisense oligonucleotides or small molecules could be employed to promote beneficial splicing events or suppress deleterious ones. By enhancing the expression of partially functional BRCA2 isoforms, it may be possible to improve DNA repair capacity in affected individuals. This strategy holds promise not only for FA-D1 but also for BRCA2-mutated cancers where splicing patterns influence treatment response. As splicing-targeted therapies gain traction, FA-D1 serves as a critical model for assessing their feasibility and efficacy in restoring genomic stability.

UNANSWERED QUESTIONS AND FUTURE RESEARCH DIRECTIONS

Despite recent progress, key questions remain regarding BRCA2 splicing in FA-D1. What governs the selection of alternative splice sites? How consistent are these patterns across patient cohorts? Do external factors like stress, cell type, or chromatin context influence BRCA2 splicing outcomes? Future research must integrate transcriptomic, proteomic, and structural analyses to decode the regulatory logic of these compensatory events. The study of 5′ terminal splicing could also inform broader questions in molecular biology, such as the evolution of gene architecture, robustness of RNA processing, and adaptability of disordered protein regions. Ultimately, unraveling these mechanisms may reshape our approach to both rare genetic syndromes and common malignancies.

Visit: https://infectious-diseases-conferences.pencis.com
Nominate Now: https://infectious-diseases-conferences.pencis.com/award-nomination/?ecategory=Awards&rcategory=Awardee
Registration page: https://infectious-diseases-conferences.pencis.com/award-registration/
Contact us: infectioussupport@pencis.com

HASHTAGS:

#FanconiAnemia, #BRCA2, #FANCD1, #DNADamageRepair, #SplicingMechanisms, #AlternativeSplicing, #GenomicInstability, #ChromosomalBreakage, #CancerGenetics, #HypomorphicVariants, #TranslationalReinitiation, #RNAProcessing, #DisorderedProteins, #GeneticCompensation, #BRCA2Splicing, #FAResearch, #GeneticTherapies, #SplicingModulators, #TranslationalGenetics, #BRCA2Function,

Public Attitudes Toward Genomic Newborn Screening in Australia | DCE Study Insights #GenomicScreening #NewbornHealth #Pencis

 

INTRODUCTION: THE FUTURE OF GENOMIC NEWBORN SCREENING

Genomic sequencing in newborn screening (gNBS) represents a major leap in early diagnosis and personalized medicine. This innovation offers the potential to identify a wider spectrum of genetic conditions beyond what traditional screening methods detect. In a large-scale study involving 2,509 Australian adults, researchers assessed public attitudes toward the value and implementation of gNBS. Findings revealed strong support, with 90% expressing interest in receiving results. This introduction highlights the scope of genomic newborn screening research, focusing on public values, cost considerations, consent models, and potential healthcare outcomes. These insights provide a foundation for evaluating the social and economic implications of integrating gNBS into public health frameworks.

PUBLIC PERCEPTION AND ACCEPTABILITY OF GENOMIC NEWBORN SCREENING

Understanding public sentiment is essential when introducing transformative technologies like gNBS. The research highlighted widespread enthusiasm for receiving genomic results, with the majority of participants prioritizing informed access to newborn health data. However, perceptions were nuanced—while people embraced the benefits of early diagnosis, concerns emerged over the inclusion of untreatable or low-penetrance conditions. These findings suggest that education and transparent communication are vital to maintain public trust and ensure successful program adoption. Tailoring implementation strategies to align with public values can significantly improve long-term acceptance.

ECONOMIC VALUE AND COST CONSIDERATIONS IN gNBS

Cost emerged as the dominant factor influencing participants' decisions about gNBS uptake. The study quantified public willingness to pay between AU$4,600 and $5,700 per newborn screened for programs that diagnose 10–50 additional cases per 1,000 newborns. These figures are critical for policymakers conducting cost-benefit analyses and designing economically sustainable gNBS programs. Balancing affordability with the promise of increased diagnostic yield can help guide the resource allocation needed for nationwide implementation.

OPTIMAL CONSENT MODELS FOR GENOMIC SCREENING PROGRAMS

Ethical implementation of gNBS requires robust, user-preferred consent models. The study revealed a strong preference (65%) for opt-in consent, reinforcing the importance of autonomy and informed decision-making in genomic healthcare. Participants favored receiving high-probability results in person from genetics professionals, although remote delivery through phone or telehealth was also acceptable. This data underscores the need for flexible yet ethically grounded consent practices that cater to diverse population preferences while ensuring clarity and patient comfort.

IMPACT OF DIAGNOSTIC YIELD ON PUBLIC SUPPORT FOR gNBS

A key driver of support for gNBS was its ability to increase diagnostic rates among newborns. Respondents showed a clear preference for models that identify more conditions early, demonstrating the value placed on clinical utility. However, enthusiasm waned for including conditions with limited treatment options or low penetrance, suggesting a trade-off between diagnostic comprehensiveness and emotional or practical burden. Future research should explore how to balance these factors to optimize diagnostic impact while respecting patient values.

INFORMING GLOBAL HEALTH POLICY THROUGH AUSTRALIAN gNBS INSIGHTS

Australia’s experience with gNBS research provides a valuable template for other healthcare systems considering similar programs. The combination of public preference data, economic valuation, and ethical considerations offers an evidence-based framework to inform global genomic screening policy. Countries aiming to integrate gNBS can use these insights to design context-sensitive programs that align with public interest and system capacities. Further cross-national studies can help adapt these findings for diverse cultural and healthcare environments.

Visit: https://infectious-diseases-conferences.pencis.com
Nominate Now: https://infectious-diseases-conferences.pencis.com/award-nomination/?ecategory=Awards&rcategory=Awardee
Registration page: https://infectious-diseases-conferences.pencis.com/award-registration/
Contact us: infectioussupport@pencis.com

Hashtags

#GenomicScreening, #NewbornGenomics, #PublicHealthResearch, #GenomicMedicine, #PrecisionHealth, #GeneticDiagnosis, #HealthcareInnovation, #gNBS, #Bioethics, #PublicPreferences, #ConsentModels, #HealthEconomics, #ScreeningPolicy, #PopulationHealth, #GenomicsInPractice, #HealthTechnologyAssessment, #GeneticScreeningEthics, #ImplementationScience, #ClinicalGenomics, #PatientCenteredCare,

"COVID-19 Impact on Seasonal Outbreak Detection: SARIMAX-LSTM Hybrid Model Explained #InfectiousDiseases #COVID19Research #Pencis"

INTRODUCTION

Seasonal infectious diseases have long posed significant public health challenges in the Republic of Korea. Influenza, norovirus, severe fever with thrombocytopenia syndrome (SFTS), and tsutsugamushi disease each follow distinct epidemiological patterns influenced by seasonal and environmental factors. However, the COVID-19 pandemic has introduced a profound disruption to global disease transmission dynamics. This study seeks to quantify the long-term patterns of these infections between 2005 and 2023, while analyzing how COVID-19 impacted their seasonality and outbreak intensity. By integrating classical time-series forecasting through the SARIMAX model with advanced deep learning via LSTM networks, and combining them in a hybrid SARIMAX-LSTM model, this research delivers robust predictive insights. Meteorological data and change point detection were employed to enhance the understanding of outbreak shifts. The goal is not only to understand historical trends but also to forecast and prepare for future outbreaks, particularly in a post-pandemic era.

EPIDEMIOLOGICAL TRENDS ACROSS TWO DECADES

The study spans 18 years, offering a comprehensive view of infectious disease seasonality in South Korea. Influenza and norovirus displayed predictable annual patterns until 2020, while SFTS and tsutsugamushi disease showed more static endemic behaviors. The onset of COVID-19 disrupted these trends, significantly reducing the incidence of influenza-like illnesses and norovirus infections. Interestingly, vector-borne diseases such as SFTS and tsutsugamushi disease did not follow this decline, suggesting that their transmission mechanisms were less impacted by pandemic-related public health interventions such as mask-wearing and social distancing. This divergence reinforces the need to categorize infectious diseases based on both their transmission modes and vulnerability to behavioral changes within the population.

IMPACT OF COVID-19 ON SEASONAL DISEASES

The global pandemic triggered a cascade of health policy shifts that influenced not only SARS-CoV-2 but also other respiratory and gastrointestinal diseases. The study reveals that the incidence of influenza sharply declined during the pandemic and has not returned to pre-pandemic levels even in recent years. Norovirus followed a different trajectory—while it dropped in 2020, it rebounded to prior levels soon after. This suggests that viral shedding and environmental persistence may play crucial roles in post-pandemic resurgence. On the other hand, the relatively stable patterns of SFTS and tsutsugamushi disease throughout the pandemic period imply limited impact from urban-centric COVID-19 interventions, further underlining the importance of ecological and vector-focused disease modeling.

ADVANCED MODELING TECHNIQUES FOR OUTBREAK DETECTION

In this study, SARIMAX, LSTM, and a novel SARIMAX-LSTM hybrid model were implemented to predict infectious disease trends. The SARIMAX model leverages temporal patterns and incorporates exogenous variables such as meteorological data. Meanwhile, LSTM neural networks process long-term dependencies in sequential data. Combining these methodologies produced a hybrid model that demonstrated superior performance in outbreak forecasting. This approach enabled the identification of subtle trend shifts and seasonal fluctuations across diseases. The application of change point detection (CPD) techniques further strengthened the models by highlighting statistically significant deviations in disease incidence, especially during the COVID-19 outbreak period. These insights are essential for early warning systems and targeted resource allocation.

DIFFERENTIAL RECOVERY AND RESURGENCE POTENTIAL

Post-COVID-19 disease dynamics have shown that not all infections recover at the same pace or pattern. Influenza, for instance, experienced a steep decline but remains suppressed compared to pre-pandemic baselines, hinting at altered immunity or sustained behavior changes. Conversely, norovirus quickly resumed its cyclical outbreaks. Predictive modeling suggests that influenza-like illness (ILI) outbreaks may resurge in the near future due to waning immunity and lowered population-level exposure. These findings stress the need to monitor evolving trends rather than assume automatic recovery of seasonal patterns. Disease-specific strategies—such as continued surveillance, targeted vaccination, and behavior-based interventions—must be developed in anticipation of these shifts.

PUBLIC HEALTH IMPLICATIONS AND STRATEGIC RECOMMENDATIONS

The differential effects of the COVID-19 pandemic on infectious disease incidence call for disease-specific public health responses. For respiratory and gastrointestinal viruses like influenza and norovirus, adaptive interventions—including enhanced surveillance during transition seasons and targeted public awareness campaigns—are critical. Vector-borne diseases, which remained stable throughout the pandemic, require sustained ecological monitoring and regional preparedness. Predictive analytics using hybrid SARIMAX-LSTM models and real-time meteorological data can serve as early warning systems. These tools empower healthcare agencies to preempt outbreaks, optimize resource allocation, and reduce the healthcare burden. Moving forward, preparedness must factor in both historical data and the new post-pandemic normal.

👉 Visit: https://infectious-diseases-conferences.pencis.com
📩 Contact: infectioussupport@pencis.com
🏅 Nominate Now: https://infectious-diseases-conferences.pencis.com/award-nomination/?ecategory=Awards&rcategory=Awardee
📝 Register: https://infectious-diseases-conferences.pencis.com/award-registration/

HASHTAGS

#InfectiousDiseases, #SeasonalDiseases, #SARIMAXModel, #LSTMForecasting, #HybridModels, #OutbreakDetection, #COVID19Impact, #InfluenzaTrends, #NorovirusSurveillance, #SFTSAnalysis, #TsutsugamushiDisease, #ChangePointDetection, #PublicHealthResearch, #EpidemiologyKorea, #DeepLearningModels, #PandemicInfluence, #DiseasePrediction, #MeteorologicalData, #HealthSurveillance, #DataDrivenHealthPolicy,

Unveiling COVID-19's Lingering Effects: A Chinese Case–Control Study | #LongCovid #PencisResearch #PostCovidImpact

 

INTRODUCTION

The emergence of breakthrough SARS-CoV-2 infections during the Omicron wave has reignited the urgency to understand factors influencing infection risk and clinical progression. This study, conducted across six provinces in China, adopts a case–control design involving over 20,000 participants to identify predictors for the incidence, persistence, and severity of symptoms after COVID-19 infection. Through matching cases and controls on age, sex, and region, and analyzing a broad range of individual-level variables using multivariate logistic regression, the study provides a comprehensive exploration of host and behavioral determinants. Key findings reveal associations between lifestyle factors, such as tea and coffee consumption or alcohol intake, and infection risk or symptom severity. Notably, both underweight and overweight status emerged as significant predictors of poor outcomes. By incorporating real-world surveillance data and considering vaccination history, this research offers critical insight into COVID-19 symptom trajectories in a post-vaccine context. Its emphasis on individualized risk profiling offers a foundation for targeted public health interventions and long-term management of post-COVID complications in Chinese adults.

DEMOGRAPHIC AND LIFESTYLE DETERMINANTS OF INFECTION

Demographic and behavioral attributes play a crucial role in shaping the risk of breakthrough SARS-CoV-2 infections. In this study, individuals with occasional alcohol consumption, tea and coffee habits, or overweight status exhibited a higher probability of infection. Conversely, weekly alcohol intake and smoking appeared to reduce infection risk, challenging conventional assumptions and suggesting complex behavioral-health interactions. Female participants showed greater vulnerability to persistent and severe symptoms, potentially reflecting hormonal, immunological, or sociocultural factors. These associations emphasize the need to consider nuanced lifestyle profiles in risk communication and prevention efforts.

THE ROLE OF COMORBIDITIES IN COVID-19 SEVERITY

The presence of pre-existing medical conditions significantly influenced both the likelihood and outcomes of SARS-CoV-2 breakthrough infections. Comorbidities were not only linked with increased infection risk but also with a higher probability of developing prolonged or moderate-to-severe symptoms. This reinforces earlier findings that chronic diseases amplify COVID-19-related complications, even in the post-vaccination era. Furthermore, individuals with a history of immunotherapy also demonstrated greater susceptibility, underscoring the importance of tailored clinical management for immunocompromised populations.

NUTRITIONAL STATUS AND WEIGHT-RELATED RISKS

Nutritional and bodyweight indicators were strongly associated with both infection susceptibility and symptom severity. The study found that being underweight or overweight elevated the odds of developing severe or persistent symptoms post-infection. This reflects a dual burden wherein both nutritional insufficiency and metabolic overload may impair immune resilience. Public health recommendations should therefore promote balanced nutrition as a critical component of infection preparedness, particularly in the face of evolving SARS-CoV-2 variants.

VACCINATION TIMING AND INFECTION OUTCOMES

A longer duration since the last COVID-19 vaccination was linked with increased infection risk in the cohort studied. This temporal association highlights waning immunity as a key vulnerability in the population, especially during high-transmission phases like the Omicron wave. The data supports the strategic administration of booster doses, particularly for at-risk individuals, to maintain protective immunity. Integration of vaccination schedules with personalized risk assessments could optimize long-term health outcomes and mitigate future surges.

TOWARD PERSONALIZED COVID-19 MANAGEMENT STRATEGIES

The study’s multifactorial findings highlight the necessity for personalized prevention and management strategies for COVID-19. No single determinant was solely responsible for infection or symptom progression; rather, an interplay of lifestyle behaviors, demographic factors, and health conditions shaped the clinical course. Public health frameworks should integrate these variables to develop adaptive strategies that are sensitive to individual profiles. From vaccination timing to nutritional advice and comorbidity management, a personalized approach can better address the long-term impacts of COVID-19 on diverse populations.

Visit: https://infectious-diseases-conferences.pencis.com
Nominate Now: https://infectious-diseases-conferences.pencis.com/award-nomination/?ecategory=Awards&rcategory=Awardee
Registration Page: https://infectious-diseases-conferences.pencis.com/award-registration/
Contact Us: infectioussupport@pencis.com

Hashtags:

#SARSCoV2, #COVID19Research, #BreakthroughInfections, #OmicronWave, #PublicHealth, #Epidemiology, #COVID19China, #CaseControlStudy, #SymptomPersistence, #SymptomSeverity, #VaccinationImpact, #LifestyleFactors, #Comorbidities, #RiskAssessment, #HealthDeterminants, #PersonalizedMedicine, #WeightAndCOVID, #BehavioralHealth, #COVIDPrevention, #EpidemicSurveillance

Excellence in Innovation Award: Celebrating Breakthroughs in Infectious Diseases Research | #Pencis #InnovationAward

                                      

                                           

INTRODUCTION

The Excellence in Innovation Award by Pencis is a prestigious global recognition that applauds the relentless efforts and trailblazing achievements of researchers in the field of infectious diseases. Designed to honor those who have redefined healthcare practices, this award acknowledges professionals whose pioneering work has led to substantial breakthroughs in understanding, diagnosing, preventing, or treating infectious diseases. As the global burden of infectious diseases continues to challenge healthcare systems, this award underscores the importance of research-driven innovation to combat both emerging and re-emerging threats. Whether by unraveling the complexities of pathogens, formulating new vaccine strategies, or implementing transformative public health measures, awardees serve as catalysts for global health improvement. This accolade not only recognizes past accomplishments but also encourages continued excellence in biomedical research, spotlighting the individuals who transform ideas into life-saving impact. By celebrating these achievements, Pencis drives a broader vision for future-forward infectious disease research worldwide.

BREAKTHROUGHS IN MICROBIOLOGICAL RESEARCH

Microbiological research forms the bedrock of many advancements recognized by the Excellence in Innovation Award. From characterizing novel bacterial strains to decoding viral genomes, award recipients have revolutionized how pathogens are identified, monitored, and understood. These breakthroughs lay the groundwork for accurate diagnostics and targeted treatments. Advanced sequencing techniques, pathogen-host interaction models, and microbial resistance profiling have enabled researchers to make landmark discoveries. Their work has deepened our understanding of pathogen evolution and transmission, enabling earlier outbreak detection and more effective interventions.

INNOVATION IN VACCINE DEVELOPMENT

Vaccines remain one of the most powerful tools in infectious disease prevention. Innovators recognized by Pencis have introduced cutting-edge technologies, such as mRNA-based platforms, nanoparticle vaccines, and thermostable formulations, that have transformed vaccine science. These efforts are crucial in addressing pathogens with high mutation rates and limited existing prophylactic options. Research acknowledged by the award often involves cross-disciplinary collaboration and long-term impact, proving vital during global health crises such as COVID-19 and Ebola. The emphasis on equitable access and immunological precision makes this field particularly commendable.

ADVANCES IN ANTIMICROBIAL RESISTANCE STRATEGIES

The growing crisis of antimicrobial resistance (AMR) has been a major focus among award recipients. Their research offers innovative approaches to counter resistant strains, ranging from novel antibiotics and combination therapies to phage therapy and antimicrobial peptides. Additionally, breakthroughs in AMR surveillance technologies have allowed better tracking of resistance trends globally. The Excellence in Innovation Award honors such critical contributions, which are indispensable in extending the efficacy of current treatments and safeguarding future generations against superbugs.

PUBLIC HEALTH INTERVENTIONS AND EPIDEMIOLOGICAL IMPACT

Innovative public health research plays a central role in shaping disease control strategies. Awardees in this category have developed data-driven interventions, improved disease surveillance systems, and modeled effective outbreak responses. Their research often informs global and national policies, strengthening health system resilience. Whether it’s through implementing digital contact tracing tools or assessing vaccination coverage disparities, their findings bridge the gap between science and real-world application. These contributions are vital to preventing and mitigating the spread of infectious diseases at scale.

TRANSLATIONAL MEDICAL RESEARCH AND THERAPEUTIC DISCOVERY

The Excellence in Innovation Award also honors researchers who translate laboratory findings into clinical applications. These individuals pioneer therapeutic discoveries, including antiviral drugs, immune modulators, and biologics tailored to infectious diseases. Translational research not only accelerates drug development but also ensures relevance to patient care. Many recipients have led clinical trials that redefined treatment protocols and enhanced survival outcomes in infectious disease cases. Their work reflects the synergy between bench science and bedside application—critical for real-world medical transformation.

🎯 Visit: https://infectious-diseases-conferences.pencis.com
📝 Nominate Now: https://infectious-diseases-conferences.pencis.com/award-nomination/?ecategory=Awards&rcategory=Awardee
🧾 Registration Page: https://infectious-diseases-conferences.pencis.com/award-registration/
📩 Contact Us: infectioussupport@pencis.com

Hashtags:

#InfectiousDiseases, #InnovationAward, #PencisResearch, #MicrobiologyBreakthrough, #VaccineDevelopment, #AMRResearch, #PublicHealth, #TherapeuticDiscovery, #TranslationalMedicine, #PathogenGenomics, #GlobalHealth, #Epidemiology, #ViralResearch, #AntimicrobialResistance, #ScientificExcellence, #BiomedicalResearch, #HealthInnovation, #DiseasePrevention, #MedicalInnovation, #FutureOfMedicine,

Ultrasound-Guided Parasternal Block in Off-Pump CABG: A Game-Changer in Cardiac Anesthesia | #Pencis

INTRODUCTION

Effective postoperative pain management is a cornerstone of recovery after cardiac surgery, particularly in off-pump coronary artery bypass (OPCAB) procedures where median sternotomy often results in significant sternal pain. This discomfort can delay recovery, extend ICU stays, and may lead to chronic postoperative sternal pain syndrome. The implementation of ultrasound-guided regional blocks has gained traction as part of Enhanced Recovery After Cardiac Surgery (ERACS) protocols. Among these, the parasternal intercostal plane block (PIPB) has shown promise in mitigating postoperative pain. This single-center retrospective cohort study evaluates the clinical efficacy of a deep, single-shot PIPB in managing acute postoperative pain among 157 OPCAB patients. By comparing those who received the block (38 patients) to a standard therapy group (119 patients), and applying propensity score matching, the study provides insight into pain outcomes, analgesic usage, extubation times, and ICU metrics. The findings offer critical evidence for incorporating PIPB into multimodal analgesic strategies.

ANALGESIC OUTCOMES AND OPIOID SPARING EFFECTS

One of the central objectives of the study was to evaluate whether deep parasternal intercostal plane blocks (PIPB) could reduce the need for opioid analgesics. Patients who received PIPB demonstrated a significantly lower requirement for piritramide at both 24 and 48 hours postoperatively. Furthermore, the total morphine equivalent (ME) requirement was considerably reduced in the PIPB group. These opioid-sparing effects are clinically relevant, particularly in light of ongoing concerns about opioid overuse and associated complications. The results confirm the potential of PIPB as a non-opioid alternative that can enhance patient safety and reduce pharmacological burden during the early recovery phase.

EVALUATION OF PAIN PERCEPTION THROUGH BPS AND NRS SCORES

Accurate assessment of patient pain perception was integral to this study’s methodology. Behavioral Pain Scores (BPS) and Numeric Rating Scores (NRS) were used to measure postoperative pain levels up to 48 hours after extubation. Results indicated that patients who received the deep PIPB reported significantly lower NRS values. These subjective pain scores further validated the block’s analgesic effectiveness. Although BPS scores were not explicitly detailed in the summary, the overall trend suggested that patients had improved comfort, leading to faster recovery and reduced reliance on emergency analgesia. This highlights the relevance of integrating both objective and subjective tools in postoperative pain evaluation.

TIME TO EXTUBATION AND EARLY RECOVERY METRICS

An encouraging finding of the study was the reduction in time to extubation among patients who underwent the PIPB procedure. Faster extubation is a critical parameter within ERACS protocols and often correlates with better pain control and overall physiological stability. The PIPB group exhibited improved readiness for weaning from mechanical ventilation, likely due to reduced opioid-induced respiratory depression and enhanced analgesia. However, while extubation times were positively affected, the study did not find significant differences in ICU length of stay. This suggests that while PIPB influences immediate postoperative recovery, additional variables impact longer-term ICU outcomes.

PROPENSITY SCORE MATCHING FOR VALIDATION

To reinforce the reliability of the study findings, a one-to-one propensity score matching analysis was performed. This statistical technique minimizes selection bias by aligning patient characteristics between the PIPB and non-PIPB groups, ensuring that observed differences in outcomes are more likely due to the intervention rather than confounding factors. Post-matching analysis reaffirmed the primary results: patients in the PIPB group required fewer intravenous analgesics and experienced improved early recovery outcomes. This strengthens the internal validity of the study and supports the adoption of PIPB in standardized perioperative care protocols for cardiac surgery.

LIMITATIONS AND FUTURE RESEARCH DIRECTIONS

While the study presents robust evidence supporting deep PIPB in OPCAB surgeries, it is not without limitations. Being a retrospective, single-center analysis, it is subject to inherent biases despite propensity score matching. Moreover, some outcomes like ICU stay, incidence of nausea, and vomiting did not differ significantly, suggesting a need for larger, multicenter randomized controlled trials to further validate findings. Future research could also explore the benefits of continuous versus single-shot PIPB, long-term pain outcomes, and quality-of-life metrics to better understand the full impact of this technique in cardiac surgical care.

Visit: https://infectious-diseases-conferences.pencis.com
Nominate Now: https://infectious-diseases-conferences.pencis.com/award-nomination/?ecategory=Awards&rcategory=Awardee
Register: https://infectious-diseases-conferences.pencis.com/award-registration/
Contact: infectioussupport@pencis.com

Hashtags

#UltrasoundGuidedBlock, #ParasternalBlock, #CardiacSurgeryPain, #OPCAB, #SternalPainRelief, #RegionalAnesthesia, #MultimodalAnalgesia, #PainManagement, #PIPB, #DeepParasternalBlock, #PostoperativeCare, #Anesthesiology, #CardiothoracicRecovery, #NRS, #BPS, #MorphineReduction, #ERACS, #AnalgesiaInnovation, #PropensityScoreMatching, #EnhancedRecovery,